Trade

Gland Pharma share price

Balanced risk
  • 36%Low risk
  • 36%Moderate risk
  • 36%Balanced risk
  • 36%High risk
  • 36%Extreme risk
  • ₹2,249.95(-0.98%)
    June 8, 2026 15:29:00 PM IST
    • NSE
    • BSE
  • Vol : 489.94 K (NSE + BSE)
    Last 20 day avg : 924.59 K

Gland Pharma is trading -0.98% lower at Rs 2,249.95 as compared to its last closing price. Gland Pharma has been trading in the price range of 2,335.00 & 2,238.70. Gland Pharma has given 32.00% in this year & 1.02% in the last 5 days. Gland Pharma has TTM P/E ratio 27.20 as compared to the sector P/E of 27.34.There are 15 analysts who have initiated coverage on Gland Pharma. There are 7 analysts who have given it a strong buy rating & 3 analysts have given it a buy rating. 2 analysts have given the stock a sell rating.The company posted a net profit of 366.68 Crores in its last quarter.Listed peers of Gland Pharma include Torrent Pharmaceuticals (-0.37%), Sun Pharmaceutical Industries (0.23%), Cipla (-0.83%).The Mutual Fund holding in Gland Pharma was at 31.78% in 31 Mar 2026. The MF holding has increased from the last quarter. The FII holding in Gland Pharma was at 7.29% in 31 Mar 2026. The FII holding has decreased from the last quarter.

  • Overview
  • Financials
  • Forecast
  • Technical Analysis
  • Peers
  • Shareholding
  • About the company
  • FAQ

Overview

  • 1 D
  • 5 D
  • 1 M
  • 3 M
  • 6 M
  • 1 Y
  • 5 Y
  • MAX
Explore on
Loading...
Key Metrics

Updated on Jun 08, 2026, 02:37 PM UTC

  • Beta
    Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
    0.20
    Low volatility
  • Debt To Equity
    The debt-to-equity ratio, indicating a company's financial leverage.
    0.03
    Lower than industry
  • Dividend Yield
    Annual dividends as a percentage of the stock price.
    0.88
    Lower than industry
  • PEG Ratio
    The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
    3.84
    Indicates overvaluation
  • P/E
    Price-to-earnings ratio based on trailing 12-month earnings
    -
  • P/B
    The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
    -
Price range
Day Range
Lowest
2,238.70
Highest
2,335.00
52 week range
Lowest
1,570.85
Highest
2,391.25
Gland Pharma News
Gland Pharma Peers
Return Comparison
Peers Comparison
Names
Technical ratingPrice%ChangeMarket CapP/EP/BDividend YieldDebt to Equity
Torrent Pharmaceuticals
Neutral
4,402.20-0.371,48,688.3567.3217.10.8317.62
Sun Pharmaceutical Industries
Neutral
1,787.700.234,27,863.4836.245.770.920.50
Cipla
Moderately Bullish
1,389.10-0.831,12,211.5722.953.870.870.81
Divi's Laboratories
Neutral
6,505.00-1.791,72,636.4878.6111.520.460.01
Dr Reddy's Laboratories
Neutral
1,275.00-0.221,06,413.7918.633.140.632.34
Mutual Fund Ownership
View all
DSP Healthcare Fund Regular Growth
NA
  • Amount Invested (Cr.) 146.26
  • % of AUM 4.94
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Growth
NA
  • Amount Invested (Cr.) 217.55
  • % of AUM 3.95
ICICI Prudential MNC Fund Regular Growth
NA
  • Amount Invested (Cr.) 53.82
  • % of AUM 3.21
Nippon India Pharma Fund - Growth
NA
  • Amount Invested (Cr.) 242.96
  • % of AUM 2.91
Mirae Asset Healthcare Fund Regular Growth
NA
  • Amount Invested (Cr.) 75.32
  • % of AUM 2.80
Gland Pharma Corporate Actions
View all
  • Board Meetings
  • AGM
  • Dividends
  • Bonus
  • Split
  • Rights
Meeting DatePurpose
2026-05-15Audited Results & Final Dividend
2026-01-28Quarterly Results
2025-11-03Quarterly Results
2025-08-05Quarterly Results
2025-05-20Audited Results & Final Dividend
About the company Gland Pharma
  • IndustryBiotechnology & Drugs
  • ISININE068V01023
  • BSE Code543245
  • NSE CodeGLAND
Gland Pharma Limited is an India-based generic injectables manufacturer. The Company specializes in sterile injectables, oncology, and ophthalmic, with a specific focus on complex injectables, New Chemical Entities (NCE)-1s, First-to-File products, and 505(b)(2) filings. The Company manufactures a range of dosage formulations, including solutions, suspensions, and lyophilized products. Its product portfolio includes delivery methods such as pre-filled syringes, vials, ampoules, bags, and dry powder injections. It also produces generic injectables in liquid, lyophilized, suspension, and pre-filled syringe forms. Its molecules include Enoxaparin Sodium, Cisplatin, Lacosamide, Rocuronium Bromide, Zoledronic Acid, Vancomycin, and others. Its therapeutic products categories include Anti Malarials, Anti-Infectives, Anti-Neoplastics, Gynecological, Hormones, and others. The Company functions primarily on a business-to-business model. Its subsidiary is Gland Pharma International Pte. Ltd.
  • Management Info
  • Srinivas SaduExecutive Chairman of the Board
  • Shyamakant GiriChief Executive Officer
  • Ravi MitraChief Financial Officer
  • Sampath PallerlamudiCompliance Officer, Company Secretary
Gland Pharma Share Price FAQs

Gland Pharma is trading at 2249.95 as on Mon Jun 08 2026 09:59:00. This is -0.98% lower as compared to its previous closing price of 2272.15.

The market capitalization of Gland Pharma is 37022.93 Cr as on Mon Jun 08 2026 09:59:00.

The average broker rating on Gland Pharma is Buy. The breakup of analyst rating is given below -

  • 7 analysts have given a strong buy rating
  • 3 analysts have given a buy rating
  • 2 analysts have given a hold rating
  • 2 analysts have given a sell rating
  • 1 analysts have given a strong sell rating

The 52 wk high for Gland Pharma is 2391.25 whereas the 52 wk low is 1570.85

Gland Pharma can be analyzed on the following key metrics -

  • TTM P/E: 27.20
  • Sector P/E: 27.34
  • Dividend Yield: 0.88%
  • D/E ratio: 0.03

Gland Pharma reported a net profit of 1027.32 Cr in 2026.

The Mutual Fund Shareholding was 31.78% at the end of 31 Mar 2026.

Quick Links
EQUITY QUICK LINKS
Gland Pharma QUICK LINKS
FROM MARKETS
RELATED LINKS
Quarterly Results
Home/Market/Market Stats/  Gland Pharma share price
✕

Wait for it…

Log in to our website to save your bookmarks. It'll just take a moment.

✕

Wait for it…

Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.